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ABSTRACT Factor Xa (FXa) has a prominent role in amplifying both inﬂammation and the coagulation cascade. In the coag-
ulation cascade, its main role is catalyzing the proteolytic activation of prothrombin to thrombin. Efﬁcient proteolysis is well known
to require phosphatidylserine (PS)-containing membranes that are provided by platelets in vivo. However, soluble, short-chain
PS also triggers efﬁcient proteolytic activity and formation of an inactive FXa dimer in solution. In this work, we ask whether
PS-containing membranes also trigger formation of an inactive FXa dimer. We determined the proteolytic activity of human
FXa toward human Pre2 as a substrate both at ﬁxed membrane concentration (increasing FXa concentration) and at ﬁxed
FXa concentration (increasing membrane concentration). Neither of these experiments showed the expected behavior of an
increase in activity as FXa bound to membranes, but instead suggested the existence of a membrane-bound inactive form of
FXa. We found also that the ﬂuorescence of ﬂuorescein attached to FXa’s active site serine was depolarized in a FXa concen-
tration-dependent fashion in the presence of membranes. The ﬂuorescence lifetime of FXa labeled in its active sites with a dansyl
ﬂuorophore showed a similar concentration dependence. We explained all these observations in terms of a quantitative model
that takes into account dimerization of FXa after binding to a membrane, which yielded estimates of the FXa dimerization
constant on a membrane as well as the kinetic constants of the dimer, showing that the dimer is effectively inactive.
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The activation of prothrombin to thrombin is a crucial step
in the blood coagulation process. It is accomplished by the
prothrombinase complex, which consists of a serine pro-
tease, factor Xa (FXa), and a protein cofactor, factor Va
(FVa), interacting on an appropriate acidic membrane
surface (1,2). The prothrombinase complex sits at the inter-
section of the classical intrinsic and extrinsic coagulation
pathways, and as such, is widely envisioned as a point of
regulation of the coagulation process. Phosphatidylserine
(PS) has been known for some time to be specifically
required for optimal prothrombinase activity (3,4). An early
article on prothrombinase showed that PS-containing
membranes enhanced the kcat/KM for human prothrombin
activation by FXa by ~8000-fold (5). A more recent study
put the increase in kcat/KM at roughly 1000, but also showed
that PS-containing membranes made activation processive
(i.e., two bonds cut without release of the substrate from
the enzyme) and directed activation through one of two
possible intermediates (6), both roles previously assigned
to factor Va (7). However, several studies that are more
recent have shown that it is not a PS-containing membrane
but primarily molecular PS that is essential for prothrombi-
nase activity. Thus, binding of a water-soluble phosphatidyl-
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0006-3495/09/10/2232/10 $2.00serine, 1,2-dicaproyl-3sn-phosphatidylserine (C6PS) to
human factor Xa also increased kcat/KM by ~200-fold and
directed activation via a single intermediate (8). Indeed,
C6PS binds to FVa to assemble an FXa-FVa complex in
solution that activates prothrombin by the same processive
mechanism as membrane-bound prothrombinase and at a
rate only a factor-of-2 less than that of the membrane com-
plex (9). Thus, molecular PS acts as an allosteric regulator
of prothrombin activation by binding to specific sites and
altering the structure and function of factors Xa and Va.
The platelet membrane is asymmetric in its lipid composi-
tion (10). This asymmetry in the platelet membrane and
membranes of other cells in contact with plasma is main-
tained by an adenosine triphosphate-driven amine-lipid
translocase that moves phosphatidylserine (PS) and phos-
phatidylethanolamine (PE) from the outer to the inner
platelet membrane leaflet (11). The expenditure of energy
to maintain PS and PE asymmetry implies that the asymme-
try must play a significant role in cell function. Activation of
human platelets leads to appearance of discrete membranous
vesicles with diameters of 80–200 nm that support the pro-
thrombinase complex (12). Platelet-derived membranous
vesicles were first described in 1967 as minute ‘‘particles’’,
termed platelet ‘‘dust’’, found in human plasma and serum
(13). These vesicles obtained from collagen-activated plate-
lets bound factor to factor Va support blood coagulation (12).
This was confirmed for complement- and thrombin-activated
platelets, and it was shown that appearance of these vesicles
corresponded with loss of PS asymmetry (14,15).
Both because of FXa’s central role in the prothrombinase
complex and because of the apparent role of PS as a signaling
doi: 10.1016/j.bpj.2009.07.043
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this enzyme is of particular interest in understanding the regu-
lation of blood coagulation. FXa, along with thrombin, has
been one of the most popular targets for the development of
anticoagulant/antithrombotic drugs, although this quest to
date has been unsuccessful. Animal model research shows
that inhibiting FXa is effective in preventing both arterial
and venous thrombosis, making FXa a popular target for
drug development (16). In addition to its role in blood coagu-
lation, FXa has a prominent role in amplifying both the inflam-
mation and coagulation cascades. In inflammation, FXa
activates PAR2 (17). Protease-activated receptors are G
protein-coupled receptors that function as cell-surface sensors
for coagulant proteases and, bybinding to effector cell protease
receptor 1, participate in several cellular events that are
involved in the inflammatory response (18). Clearly, FXa
regulation is of considerable interest in biomedical science.
In addition to activating factors Xa and Va, C6PS binds to
bovine FXa to induce Ca2þ-dependent dimerization (19).
Recent results showed that human FXa dimerizes in the pres-
ence of soluble PS and 5 mMCa2þ and that the dimer is ~107
times less active than the monomer (20). We address here the
following questions:
1. Does FXa form dimers on PS-containing membranes?
2. If so, is the dimerization constant in a potentially physio-
logically significant range?
FIGURE 1 Initial rate of Pre2 activation to thrombin by FXa. The initial
rate of thrombin (IIa) formation was determined at 37C as a function of
increasing concentration of FXa at different concentrations of Pre2:
[Pre2] ¼ 250 nM (B), 500 nM (,), 750 nM (6), 1000 nM (>), and 1250
nM (7). Initial rates were determined in buffer A (50 mM Tris, 150 mM
NaCl, and 0.6% PEG, pH 7.4) containing 4 mM CaCl2, using the substrate
S-2238 as described in Experimental Procedures in the Supporting Material.
The curves drawn through the symbols are straight lines, the slopes of which
are R1 (as described in Appendix A in the Supporting Material) for different
[Pre2]. (Inset) Linear dependence ofR1 on [Pre2],which demonstrates that the
reaction follows Michaelis-Menten kinetics under our conditions and gives,
as the slope of this plot, kcat/KM¼ 945 2M1 s1 for free FXa. By globally
fitting all five data sets to the Michaelis-Menten model (20), we obtained the
same kcat/KM as well as KM ¼ (105 1) mM.3. Are FXa dimers equally inactive on PS-containing
membrane as in solution?
We have recorded the florescence and fluorescence lifetime
of labeled human DEGR-Xa and finally the fluorescence
anisotropy of Fluorescein-Glu-Gly-Arg-chloromethylke-
tone-modified FXa (FEGR-Xa) in response to 25% PS-con-
taining membranes. We have also determined the proteolytic
activity of human FXa toward human Pre2 as a substrate both
at fixed membrane concentration (increasing FXa concentra-
tion) and at fixed FXa concentration (increasing membrane
concentration). A model that takes into account FXa dimer-
ization upon binding to a membrane successfully described
all our data with surface dimer dissociation constants of
1.2  1014 mole fraction for human FXa and 2.6  1010
mole fraction for human DEGR-Xa or FEGR-Xa. We
conclude that human FXa forms an essentially inactive dimer
on PS-containing membranes even at very low membrane
surface concentrations and that labeling the active site serine
inhibits dimer formation.
MATERIALS AND METHODS
See Experimental Procedures in the Supporting Material.
RESULTS
FXa activity in solution
The initial rate of activation of Pre2 by factor Xa in solution
(50 mM Tris, 150 mM NaCl, 0.6% PEG, and 4 mM Ca2þ,
pH 7.4 at 37C) was determined at different Pre2 concentra-
tions as a function of FXa concentration (Fig. 1). For each
Pre2 concentration, the initial rate of thrombin formation
was proportional to the FXa concentration, with a different
proportionality constant, K([Pre2]), for each Pre2 concentra-
tion. The concentrations of Pre2 used in these experiments
were comparable to, and sometimes larger than, the FXa
concentrations, meaning that these reactions cannot be
assumed to follow pseudo second-order reaction kinetics
(initial rate ¼ kcat/KM[S][E] for [S] << KM) that derive
from the steady-state (Briggs-Haldane) treatment of the
Michaelis-Menten model. However, the kcat/KM for Pre2
activation to thrombin under appropriate steady-state condi-
tions is quite small (86 5 7 M1 s1) and the KM is large
(KM >> 2 mM) (6), implying that, at the highest [Pre2]
(250 nM), the rate was only ~0.004 nM IIa/s and that only
~0.5% of Pre2 was consumed in the time during which our
experiments were performed. If we assume that delivery of
substrate to enzyme is close to diffusion-controlled, the
rate of enzyme-substrate complex formation should be sub-
stantially greater than the rate of product formation. Thus,
enzyme and substrate should be in equilibrium with ES com-
plex and the rate of product appearance should be roughly
equal to the rate of ES disappearance and thus should
be zkcat/KS, where KS is the equilibrium constant for ESBiophysical Journal 97(8) 2232–2241
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rium with E and S. This conclusion is consistent with two
observations. First, the time course for thrombin appearance
was linear and passed through zero, consistent with steady-
state conditions. Second, we plot in the inset to Fig. 1 the pro-
portionality constant K ([Pre2]) versus Pre2 concentration,
showing a linear relationship with slope K*. This makes it
clear that, for our experimental conditions,R¼K*[Pre2][Xa].
The value of K* obtained from the inset to Fig. 1 was
94M1 s1. In addition, all five data sets were simultaneously
fitted with Eq. A1 in the Supporting Material. The apparent
second-order rate constant obtained from the global fit is
K* ¼ 94 5 2 M1 s1, exactly as obtained from the inset
to Fig. 1. We conclude that the initial rate of Pre2 activation
under our conditions is appropriately represented as second
order in enzyme and substrate concentrations. The agreement
of K* with the kcat/KM reported previously (865 7 M
1 s1)
(6) argues strongly thatK*¼ kcat/KM for Pre2 activation under
our conditions, and that our results can be analyzed in terms of
the steady-state Michaelis-Menten formalism.
FXa activity in the presence of PS-containing membranes
It is widely reported that PS-containing membranes enhance
the rate of prothrombin (5,21) or Pre2 activation (6). Fig. 2 A
shows the initial rate of Pre2 conversion to thrombin (IIa) by
FXa (300 nM) as a function of FXa concentration at three
different concentrations of PS-containing membranes (5,
50, and 150 mM) in buffer A containing 4 mM Ca2þ. At
all three membrane concentrations, the initial rate did not
increase proportionally with FXa concentration as one might
expect it should, and the functionality was different at the
three membrane concentrations. Initial rates obtained at a
constant FXa concentration (300 nM) and 4 mM Ca2þ but
different membrane concentrations showed that the initial
rate of activation actually dropped with addition of small
amounts of membranes under certain conditions and reached
a minimum at membrane concentrations of ~15–20 mM
phospholipid (Fig. 2 B). Because the substrate in our exper-
iment (Pre2) is not membrane-bound, this cannot reflect
surface crowding and must mean that the membrane
somehow inhibits FXa proteolytic activity at low membrane
concentration, exactly the opposite of what current thought
would predict. At higher membrane concentrations (>20 mM),
this inhibitory effect disappeared and membranes enhanced
FXa activity, as has been widely reported in previous publi-
cations (5,22,23). An experiment performed in buffer A con-
taining 1 mM Ca2þ did not show the anomalous behavior
seen in Fig. 2 B, and was well represented in terms of a simple
surface-binding isotherm (line in the inset) giving an
apparent Kd of 2205 200 nM and stoichiometry of 63 lipids
per bound FXa (inset between Fig. 2, B and C).
Since a soluble form of phosphatidylserine (C6PS) trig-
gers formation of an inactive FXa dimer in solution
(19,20), it is reasonable to hypothesize that our current
results can be explained by FXa dimerization on a PS-con-
Biophysical Journal 97(8) 2232–2241taining membrane. To test this interpretation, we used the
model developed in Appendix A in the Supporting Material
that takes into account FXa binding to a membrane followed
by FXa dimerization on the membrane surface (Eqs. A1 and
A4 in the Supporting Material). This model has several
parameters that must be set either from previous experiments
or by fitting to our experimental data. Binding of FXa to PS-
containing membranes has been studied using a variety of
techniques (21,24–28), which yielded varying results for
the FXa membrane dissociation constant ranging from
Kd ¼ 33 nM (28) up to Kd ¼ 2700 nM (21). If FXa does
dimerize on PS-containing membranes at 4 mM Ca2þ, all
measured binding constants would be apparent binding
constants for FXa binding as a monomer but with monomer
binding linked to dimer formation. Thus, we allowed Kd,Xa
to adjust as a free parameter during description of our data
with the dimer model. The surface dimer dissociation
constant Kdimerd; Surface and kcat/KM for the dimer (kcat/KM2)
were also allowed to adjust. We used our previously reported
stoichiometry of FXa monomer membrane binding
ðNXaPL ¼ 63Þ (24), which takes into account lipids from
inner and outer monolayers. Another, more recent estimate
(52 lipids/ FXa) (27) is consistent with this. The stoichiom-
etry of FXa dimer binding ðNðXaÞ2PLÞ was also adjusted.
We used a second-order rate constant (kcat/KM) for
FXa monomer in solution as obtained from Fig. 1 (94 5
2 M1 s1) and used a previously published estimate (9000
M1 s1) (20) for a monomer bound to a PS-containing
membrane. In summary, we used four adjustable parameters
ðKdimerd; Surface; Kd; Xa; NðXaÞ2PL; kcat=KM2Þ, to describe globally
four sets of data in two types of experiments (dependence of
FXa activity on FXa concentration in Fig. 1 A and titration
of FXa activity by phospholipid in Fig. 1 B). The success of
our dimer model in predicting both sets of experiments is
illustrated by the model-generated lines through the data in
Fig. 2, A and B, and by the random distribution of residuals
shown above each set of data. The initial decrease in activity
upon addition of PS-containing membranes was explained by
the dimer model using the best-fit surface dimer dissociation
constant, Kdimerd; Surface ¼ ð40525Þ  1015 mol/(dm)2, which
corresponds to a solution dimerization constant
Kdimerd; Solution ¼ 1 nM calculated at [PL] ¼ 10 mM (see Eq. A10
in the Supporting Material for comparison of surface and
solution dimer dissociation constant units). The fitted value
for stoichiometry of a dimer was found to be NðXaÞ2PL ¼ð1:250:1Þ  NXaPL ¼ 7756. The analysis predicted that
the FXa dimer was inactive (kcat/KM~ 0M
1 s1), as reported
for the dimer in solution (20). In Fig. 2C, we plot the predicted
initial rate of Pre2 activation versus phospholipid concentra-
tion for several values of the surface dimer dissociation
constant (from bottom to top: Kdimerd; Surface ¼ 1; 10; 30; 50;
and 80  1015 mol/(dm)2). This demonstrates that tighter
dimer formation results in greater initial inhibition of activity
by added phospholipid, as would be expected if the
membrane-bound dimer has little or no activity. The slope
Inactive Factor Xa Dimer on PS-Containing Membranes 2235FIGURE 2 Global analysis of the initial rate of Pre2 activation by FXa in
the presence of 25% PS/DOPC membranes. The initial rate of thrombin
(IIa) formation was determined at 37C using the substrate S-2238 asof initial rate versus lipid concentration ðvr=v½PL Þ shows
a sigmoidal dependence on the log of the dimer dissociation
constant (Fig. 2 D), with the slope being negative below
Kdimerd; Surfacez50  1015 mol/(dm)2— corresponding to a
solution dimer dissociation constant Kdimerd; Solutionz1:2 nM
calculated at [PL] ¼ 10 mM.
Response of DEGR-Xa ﬂuorescence to titration
with PS-containing membranes
DEGR-Xa fluorescence emission intensity was recorded as
a function of increasing concentration of PS-containing
membranes in the presence of 2 and 4 mM Ca2þ. The emis-
sion intensities of DEGR-Xa measured at 2 mM Ca2þ and
normalized as described in Methods in the Supporting Mate-
rial are plotted in the inset to Fig. 3 A as a function of the
added PS membrane concentration. These data were ana-
lyzed with a simple absorption isotherm model as described
in Banerjee et al. (8), with best fit lines shown drawn through
the data. The apparent dissociation constants obtained in this
way at 2 mM CaCla (open symbols) decreased roughly
described in Experimental Procedures in the Supporting Material. The
concentration of Pre2 was 0.5 mM in buffer A with 4 mM CaCl2. (A) The
rate of activation was monitored as a function of increasing concentration
of FXa at different concentrations (B, 5 mM; ,, 50 mM; and6, 150 mM)
of 25% (PS) membrane. The plot above the frame shows the deviation of
experimental data from a value predicted by the dimerization model relative
to the average standard error (RexpRfit)/smean. (B) The rate of Pre2 activation
wasmonitored at 300 nMFXa in buffer Awith 4mMCaCl2 in the presence of
different concentrations of 25% PSmembrane. The error bar for each point is
the standard error froma linear fit to six time points. The curves drawn through
the symbols indicate the global fit of the data to a dimerization model as
described in Appendix A in the Supporting Material, which predicts that
a dimer is inactive and gives a dimer dissociation constant on a surface
Kdimerd; Surface ¼ (405 25)  1015 mol/(dm)2. This corresponds to a solution
dimer dissociation constant of Kdimerd; Solution ¼ 1 nM calculated at [PL] ¼ 10
mM. The plot above the frame shows the deviation of experimental data
from a value predicted by the dimerization model relative to the average stan-
dard error Rexp  Rfit)/smean. The inset to the panel between panels B and C
shows data obtained in a similar experiment but at 1 mM Ca2þ. The reduced
c-square for the global fit shown in panels A and Bwas c2=n ¼ 1:48, and the
normalized c-square
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
c2=n
p ¼ 1:22: c2=n ¼ 1=nP
N
ðyi;exp  f ðxiÞÞ2=s2i;exp,
where N is the number of observations; yi,exp is the (observed) mean depen-
dent quantity; s2i is variance in yi,exp; xi is the independent variable; f is the
assumed relationship between xi and yi,exp (i.e., the model developed in
Appendix A in the Supporting Material); f(xi) is predicted yi value; and
n ¼ N  p  1, where p is the number of fitting parameters. A normalized
reduced c-square close to 1 indicates that the model provides an adequate
description of the data. Since n is large (75 data points), a reduced c-square
of 1.48 corresponds to a probability for the null hypothesis (ac-square greater
than this is possible due to random variations in the data) of <0.01. (C) The
rate of activation of Pre2 by 300 nM FXa as predicted with the dimerization
model is plotted versus surface dimer dissociation constants (from bottom to
top:Kdimerd; Surface)¼ 1, 10, 30, 50, and 80 1015 mol/(dm)2 , which correspond
to Kdimerd; Solutionz 0.03, 0.3, 0.8, 1.3, and 2.1 nmol calculated at [PL]¼ 10 mM.
(D) The initial slope (in rate/membrane concentration units) of curves pre-
dicted as described in panel C ðvr=v½PL Þ [PL]¼0 varied with the base 10 loga-
rithm of the FXa dimer dissociation constant ðKdimerd; SolutionÞ in solution units
(calculated at [PL] ¼ 10 mM). Note also that this slope is predicted to be
zero at Kdimerd; Solution z 1.3 nMðKdimerd; SurfaceÞ ¼ 50  1015 mol/(dm)2.Biophysical Journal 97(8) 2232–2241
2236 Koklic et al.FIGURE 3 Fluorescence intensity studies of DEGR-Xa. (A) DEGR-Xa
binding to membranes depends on DEGR-Xa concentration. (Inset)
DEGR-Xa binding to 25% PS/DOPC membranes ([PL]) was monitored at
23C as a relative fluorescence change as PL was added at different concen-
trations of DEGR-Xa (6, 10 nM;,, 73 nM; andB, 100 nM) in buffer A
containing 2 mM Ca2þ. (Main plot) Open symbols show apparent dissocia-
tion constants for DEGR-Xa binding obtained from the data shown in the
inset fit (inset symbols are consistent with main plot) to a simple binding
model (8). (B1 and B2) Global analysis of DEGR-Xa membrane binding
Biophysical Journal 97(8) 2232–2241linearly with increasing concentration of DEGR-Xa. These
results are consistent with DEGR-Xa dimerization on a
membrane, since the concentration of membrane-bound
DEGR-Xa monomer would be depleted by dimer formation,
thus shifting by mass action the binding reaction toward
bound DEGR-Xa. We performed similar experiments at
4 mM CaCla (data shown in Fig. 3 B2) and attempted to
analyze these with a simple adsorption isotherm (dashed
lines in Fig. 3 B2). It is clear that this model will not account
for the data up to high membrane concentrations. If we
analyzed data only to 30 mM membranes (a concentration
range in which surface dimerization of FXa should be opti-
mized), effective Kd values in the range of 10–30 nM were ob-
tained. These are much smaller than Kd values obtained at 2
mM Ca2þ (Fig. 3 A), consistent with our previous report that
PS-stimulated bovine FXa dimer formation in solution is
strongly Ca2þ-dependent, with dissociation constants
decreasing with increasing Ca2þ concentration (19). These
results also help explain how literature estimates for the Kd for
FXa binding to membranes could range from ~30 nM to 3 mM.
The titrations in Fig. 3 B2 alone were insufficient to esti-
mate the DEGR-Xa dimerization constant on the membrane
surface. To obtain this estimate, we needed the intensities
of dimer and monomer fluorescence. As a result, the exper-
iments in Fig. 3 B1 were performed, in which DEGR-Xa
fluorescence intensity was recorded with increasing concen-
tration of DEGR-Xa in the absence (squares) and presence of
15 mM PS/DOPC (25:75) vesicles. Global analysis of the
results shown in Fig. 3, B1 and B2, using the dimer model
described in Appendix B in the Supporting Material,
provided a good description of the data at 100 nM (squares)
using either (B1) DEGR-Xa or (B2) membranes as titrant. (B1) Fluorescence
intensity of DEGR-Xa (scattering and background subtracted) in Buffer B
containing 4 mM CaCl2 at 23
C as a function of increasing DEGR-Xa
concentration at different concentrations (, 0 mM; and -, 15 mM) of
25% PS/DOPC membranes. (B2) Fluorescence intensity of DEGR-Xa (B,
50 nM; ,, 100 nM; and>, 150 nM) at increasing concentrations of 25%
PS/DOPCmembranes. Data in both frames were fitted globally to the dimer-
ization model (Appendices A and B in the Supporting Material) (solid lines),
yielding a surface dimer dissociation constant Kdimerd; Surface ¼ ð552Þ  109
mol/(dm)2 for DEGR-Xa, which corresponds to a solution dimer dissocia-
tion constant Kdimerd; Solution ¼ 140 mM calculated at [PL]¼ 10 mM. Dotted lines
show fits to a model that assumes that DEGR-Xa can bind to membranes
only in its monomer form. Reduced c-square for the global fit equals
c2=n ¼ 2:53, and normalized c-square ﬃﬃﬃﬃﬃﬃﬃﬃﬃc2=np ¼ 1:59, The p value for
the null hypothesis is <0.02. (C) DEGR-Xa fluorescence lifetime during
titration with 25:75 PS/DOPC membranes. DEGR-Xa (300 nM) was titrated
with 25% PS/DOPC membranes in buffer B containing 4 mM Ca2þ at 23C,
and its fluorescence lifetime was resolved into three lifetime components
using software supplied with the Spex FluoroLog-3 phase and modulation
spectrofluorometer (HORIBA Jobin Yvon, Edison, NJ). Fractional ampli-
tudes of lifetime components with lifetime t z 7.4 ns (), 13 ns (B), and
0.5 ns (6) are plotted, along with the relative proportion of DEGR-Xa in
dimer form (solid line) as predicted by the dimer model using the dimeriza-
tion constant obtained from the global fit shown in panel B. (Inset) Phase and
modulation of the signal measured at low lipid concentration [PL] ¼ 15 mM
(, phase; -, modulation) and high lipid concentration [PL] ¼ 300 mM (B,
modulation; ,, phase).
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description of the data at 50 nM DEGR-Xa (circles), as
shown by the solid lines through data points. Clearly, a
simple monomer-binding model cannot describe data ob-
tained at 100 nM and 150 nM DEGR-Xa concentrations,
whereas the dimer model developed in Appendix A in the
Supporting Material can. However, the dimer model showed
significant residuals at low lipid concentration at 50 nM
DEGR-Xa, whereas the monomer-binding model had more
randomly distributed residuals at this concentration of
DEGR-Xa. It should be noted that both the fluorescence
intensity and the contribution from dimers were quite low
at 50 nM DEGR-Xa, making meaningful analysis more diffi-
cult at this low concentration.
The dimer model analysis yielded a surface dimerization
constant of Kdimerd; Surface ¼ 552 nmol/dm2 for DEGR-Xa
compared to Kdimerd; Surface ¼ 40525 fmol/dm2 for FXa, which
was obtained from our analysis of activity data (Fig. 2). The
DEGR-Xa surface dimer dissociation constant corresponds
to a solution dimer dissociation constant of Kdimerd; Solution ¼
140 mM (also calculated at 10 mM PS membrane), which
compares to Kdimerd; Solution ¼ 1 nM for FXa. Clearly, DEGR-Xa
dimers formwith roughly 105-fold lower dimerization affinity
than seen for FXa dimer formation, presumably because the
active site is involved directly in or linked to dimer contact
sites. Analysis of the data in Fig. 3, B1 and B2, also yielded
estimates of the fluorescence intensities (relative to solution
monomer fluorescence, Ffree) of membrane-bound monomer
ðFmonomer=Ffree ¼ 0:9350:06Þ and dimer (~0 but constrained
to be R0) DEGR-Xa, thus accounting for the decrease fol-
lowed by an increase of fluorescence seen for lipid titration
of 150 nM DEGR-Xa (Fig. 3 B1, triangles).
Response of DEGR-Xa ﬂuorescence lifetime to titration
with PS-containing membranes
To obtain additional evidence for DEGR-Xa dimerization on
PS-containing membranes, 300 nM DEGR-Xa was titrated
with 25:75 PS/DOPC membranes in buffer B containing
4 mM Ca2þ at 23C. Fluorescence lifetime data were ob-
tained as described in Methods (see the Supporting Material)
using the PhaseMax fluorometer from HORIBA Jobin Yvon
(Edison, NJ) and the Lifetime Modeling Application soft-
ware developed by the same company. At each lipid concen-
tration, three lifetime components were resolved: t1¼ 0.55
0.3 ns, t2¼ 7.45 2.4 ns, and t3¼ 13.25 1.4 ns. Although
the signal was measured at 16 different frequencies that span
a considerable range, we were unable to resolve more than
three lifetime components. The fractional contributions of
each component are plotted in Fig. 3 C as a function of lipid
concentration (t1, open triangles; t2, solid circles; and t3,
open circles). At zero lipid, the data were explained in terms
of only two components. The shortest-lifetime component
had fractional amplitude that was roughly constant across
all lipid concentrations, whereas that of the long-lifetimecomponent (t3 ¼ 13.2 ns) decreased and subsequently
increased in amplitude as lipid concentration increased.
The second component (t2 ¼ 7.4 ns) appeared only in the
presence of membranes, and its fractional amplitude in-
creased and subsequently decreased with increasing mem-
brane concentration (i.e., its behavior was approximately
opposite to the behavior of component 3). These results
show that two DEGR-Xa species coexist in the presence of
membranes. This offers direct evidence that two forms of
DEGR-Xa coexist and further supports the monomer/dimer
equilibrium in terms of which we have interpreted the data
in Figs. 1–3. In this interpretation, the lifetime of the mono-
mer should correspond to component 3 (t3¼ 13.2 ns), which
is one of the two components present in the absence of
membranes. A small amount of component 1 (t1z 0.5 ns)
is present under all conditions and presumably is not sensi-
tive to the state of oligomerization of DEGR-Xa. Component
2 (t2 ¼ 74 ns) should correspond to dimers, as its contribu-
tion increases as DEGR-Xa binds to membranes and dimer-
izes and then decreases as dimers dissociate with increasing
available surface. To test this interpretation, we plot as a solid
line in Fig. 3 C the fraction of DEGR-Xa predicted to exist as
dimer under the conditions of this experiment as derived
using the dimer model (Appendix A in the Supporting Mate-
rial) and the Kdimerd; Surface obtained from global fitting of the data
in Fig. 3, B1 and B2. It is clear that the predicted fraction of
dimer correlates well with the behavior of component 2 (t2¼
74 ns) from the lifetime analysis. In the dimer interpretation,
this component should decrease at sufficiently high mem-
brane concentration because dimer dissociates into monomer
as the surface concentration of DEGR-Xa decreases, as
predicted by the dimer model (solid line).
FEGR-Xa ﬂuorescence anisotropy during titration
with 25/75 PS/DOPC membranes
Although the results presented thus far offer strong evidence
in favor of surface dimerization of FXa and DEGR-Xa, they
do not provide direct physical evidence for close approach of
two FXa molecules. To demonstrate this, we used a form of
fluorescence resonance energy transfer in which one fluores-
cein chromophore transfers the energy of its excited state to
another nearby fluorescein, a process termed nonradiative
homotransfer (29). As for all fluorescence resonance energy
transfer processes, homotransfer depolarizes fluorescence
emission, since orientational information is not preserved
during the transfer process. In this way, depolarization of
fluorescein emission can serve as a useful tool for detecting
protein oligomerization. Fig. 4 shows the fluorescence
anisotropy (Fig. 4 A) and fluorescence intensity (Fig. 4 B)
of 150 nM FEGR-Xa titrated with 25:75 PS/DOPC mem-
branes in buffer B containing 4 mM Ca2þ at 23C. Fluores-
cence anisotropy (solid circles) decreased after addition of a
small amount of PS-containing membranes. As more mem-
branes were added, the fluorescence anisotropy increasedBiophysical Journal 97(8) 2232–2241
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membranes. (A) FEGR-Xa (150 nM) in buffer B containing 1 mM Ca2þ (,)
or 4 mM Ca2þ () was titrated with 25% PS/DOPC membranes, and its fluo-
rescence anisotropy is plotted versus PS-containing membrane concentra-
tion ([PL]) before (, and ) and after (A) addition of detergent. (Inset)
Fluorescence anisotropy increase of FEGR-Xa after addition of increasing
amounts of FXa in the presence of 10 mM 25% PS/DOPC membrane.
Anisotropy was fitted using a model similar to the one in Appendix B in
the Supporting Material with the addition of competition between FXa
and FEGR-Xa. The data were fitted with only one parameter: Kdimerd; Surface for
FEGRXa-FXa dimer, which was similar to the dimer dissociation constant
for FXa dimer; all other parameters were used as obtained from previously
described experiments. Obtained reduced c-square is 2.98, and normalized
c-square is 1.73. The p value for the null hypothesis is <0.01. (B) Fluores-
cence intensity (relative to intensity at [PL] ¼ 0) of FEGR-Xa is plotted
versus PS-containing membrane concentration ([PL]) in buffer containing
4 mM Ca2þ (). Solid lines through the data in both frames were obtained
from the best global fit of the dimer model to the data, as described in
Appendix C in the Supporting Material. The dashed line in panel A shows
the fraction of FEGR-Xa present as monomer plus free species (i.e.,
1-Xdimer), as derived using K
dimer
d; Surface ¼ ð0:850:6Þ  109 mol/(dm)2 as
obtained from the global fit. Reduced c-square for the global fit equals
c2=n ¼ 2:13, and normalized c-square ﬃﬃﬃﬃﬃﬃﬃﬃﬃc2=np ¼ 1:46. The p value for
the null hypothesis is <0.02.Biophysical Journal 97(8) 2232–2241and ultimately reached the anisotropy of free FEGR-Xa in
solution (i.e., at [PL] ¼ 0 mM). The decrease in fluorescence
anisotropy indicates close juxtaposition of fluorescein moie-
ties on different FXa molecules and provides direct evidence
of FEGR-Xa self-associated upon binding to PS-containing
membranes. The return of anisotropy to that of free FEGR-
Xa at high membrane concentration indicates that self-asso-
ciation reverses upon dilution of FEGR-Xa on the membrane
surface. After addition of detergent to the membrane-rich
sample (solid diamond at [PL] ¼ 500 mM), the anisotropy
was that of free FEGR-Xa in solution (horizontal dashed
line), confirming that FEGR-Xa behaves like a solution
monomer at sufficiently high dilution on a membrane
surface. Fluorescein anisotropy also remained constant
when FEGR-Xa was titrated with 25:75 PS/DOPC mem-
branes in buffer B containing 1 mM Ca2þ (open squares),
a condition under which FEGR-Xa binds to membranes
but does not dimerize. This again confirms that binding of
FEGR-Xa to membranes does not change fluorescein
fluorescence anisotropy. We have also plotted in Fig. 4 B
the FEGR-Xa fluorescence intensity as a function of added
PS/DOPC membrane concentration.
Based on these data, it appears that the fluorescence inten-
sity of the membrane-bound FEGR-Xa monomer is the same
as that of FEGR-Xa in solution (normalized to 1). As
described in Appendix C in the Supporting Material, these
intensity data are required to analyze our FEGR-Xa anisot-
ropy data in terms of the dimerization model developed in
Appendix A in the Supporting Material. The curves resulting
from a global fit of the data in Fig. 4, A and B, are shown as
solid lines in Fig. 4, A and B. This fit was obtained using
rmonomer ¼ rfree z 0.1595 (horizontal line in Fig. 4 A) and
varying rdimer from 0 to 2  rfree and varying Kdimerd; Surface and
Fdimer/Ffree to minimize the sum of mean-squared deviations
of the data in panels A and B from values calculated via the
dimer model (c2). The value of c2 decreased steeply as
rdimer/rfree decreased but was insensitive to its value for
rdimer/rfree % 0.87, which corresponds to R/R0 % 0.75 (see
Eq. C1 in the Supporting Material). Thus, we can say only
that the two active-site located flouresceins in the FEGR-
Xa dimer are separated by <~37 A˚. The value of Fdimer/Ffree
varied in this range from 0.34 to 0.25, with lower values
corresponding to lower rdimer/rfree. The surface dimer disso-
ciation constant for FEGR-Xa did not vary significantly in
this range, with Kdimerd; Surface ¼ 0:750:6 nmol/dm2, which
compares to Kdimerd; Solution ¼ 19 mM, calculated at [PL] ¼
10 mM. These results convincingly demonstrate that FEGR-
Xa self-associates on a PS-containing membrane and
strongly suggest that the aggregate form is a dimer, as we
have demonstrated unambiguously for FXa in solution (19).
DISCUSSION
Factor Xa dimerizes in the presence of water-soluble C6PS
(19) to dimers that are nearly inactive in solution. Based
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(27) proposed that FXa but not FX might dimerize on
a membrane. In addition, Husten et al. (30) suggested from
fluorescence data that DEGR-Xa might form oligomers on
binding to PS-containing membranes. However, these claims
were not taken seriously since these reports offered no direct
evidence for dimer formation or quantitative analysis of
observations in terms of a dimerization model. This study
provides both. We present five independent lines of evidence
for dimer formation, each of which is quantitatively consis-
tent with a dimerization model:
1. Activity decrease upon binding to membranes (Fig. 2).
2. Effective Kd for membrane binding as a function of
membrane concentration (Fig. 3 A).
3. Anomalous binding isotherms for DEGR-Xa (Fig. 3, B1
and B2).
4. Two DEGR-Xa fluorescence lifetime components vary
with membrane concentration (Fig. 3 C).
5. FEGR-Xa anisotropy decrease due to nonradiative homo-
transfer (Fig. 4).
In trying to explain our observations, we used a dimer model,
both because this is the simplest possible oligomer model
and because FXa forms a dimer in solution when bound to
soluble C6PS (19,20). Furthermore, the same surface dimer-
ization model (Appendices A–C in the Supporting Material)
explains all these anomalous behaviors. We conclude that
FXa (and even its active-site derivatized forms) form dimers
on PS-containing membranes.
One of the most interesting aspects of this phenomenon is
that addition of PS-containing membranes to FXa at near
physiological concentrations leads to a drop, not an increase,
in its proteolytic activity. To demonstrate this, we used a
substrate that does not bind to membranes and does not block
the membrane surface (evidenced by proteolytic rate unaf-
fected by membrane concentration at low FXa concentration
(8)), Pre2. The rate of Pre2 conversion by FXa at 10 mM
calcium was shown some time ago to be only slightly
increased (approximately twofold) by the presence of phos-
pholipid membranes (1:1 dioleoylphosphatidylcholine/dio-
leoylphosphatidylglycerol) as compared to the absence of
membranes (31). Since soluble PG does not stimulate FXa
activity against prothrombin (32) but soluble PS produces
a 500-fold increase (8), the small effect previously reported
must have been a nonspecific change in the protein due to
absorption to a PG-containing membrane surface (24).
However, in the experiments summarized in Fig. 2 B, addi-
tion of PS-containing membranes leads to a twofold decrease
in activity rather than the 500-fold increase we have reported
previously (6). This also contrasts with reports from other
groups (e.g., (5,22)) that PS-containing membranes increase
FXa activity by anywhere between 20- and 7000-fold, de-
pending on the experimental conditions. This discrepancy
results from the fact that the studies presented here were per-
formed with high concentrations of FXa, akin to those thatmight exist in a platelet plug (potentially 150–200 nM if
all FX is activated), whereas most of the earlier studies
were carried out with 1–10 nM FXa.
Now that we have demonstrated the existence of a
membrane-assembled FXa dimer, it is reasonable to ask
whether it may be similar to the C6PS-assembled species.
At 4 mM Ca2þ, the dissociation constant for the solution-
phase human FXa dimer is ~80 nM (20), whereas the surface
dissociation constant obtained from fitting the data in Fig. 2
Kdimerd; Surface ¼ (40 5 25)  1015 mol/(dm)2 corresponds to
a solution dissociation constant of 10, 1, or 0.1 nM at 1,
10, or 100 mM membranes. Expressed in the same units
(nM), the solution and surface dimer dissociation constants
are comparable, except that the membrane-associated con-
stant is smaller, as would be expected if localization of the
monomer to a membrane reduces the unfavorable entropy
of self-association. In addition, both the membrane- and
C6PS-assembled dimers are essentially inactive toward pre-
thrombin 2 as a substrate. Based on these observations, it
seems that the solution and membrane-bound dimers are
comparable. Since head-to-head or head-to-tail dimers
would be difficult to imagine on a membrane, it is likely
that both are side-by-side complexes. Based on this conclu-
sion, on our fluorescein nonradiative homotransfer results,
and on lysine acetylation results, it is concluded elsewhere
that the structure of FXa in the dimer must be significantly
different from monomer structures proposed based on crys-
tallographic data (20).
Our results also make it clear that the dimer interface must
either involve the enzyme active site or be linked to the active
site, since labeling of this site results in a significantly higher
surface dimerization dissociation constant (0.7 and 5 nmol/
dm2 for FEGR-Xa and DEGR-Xa, respectively) than appears
to apply to unlabeled FXa dimerization (0.04 nmol/dm2).
This is consistent with the fact that C6PS-triggered DEGR-
Xa dimerization is barely detectable in solution (20). In the
dimer, fluorescein depolarization suggests that fluorescein
moieties linked to the active site are within 37 A˚ of each other
(Fig. 4). The active site is not blocked in the dimer, since it
remains active against a synthetic tri-peptide substrate (20).
However, the membrane-bound dimer is essentially inactive
toward a protein substrate, prethrombin 2, exactly as was
observed for a soluble dimer assembled in solution through
binding of soluble C6PS, suggesting that dimer formation
interferes with a substrate exosite rather than with direct
interaction with the active site (20).
Since it is now established that PS binding triggers forma-
tion of inactive dimers both in solution and on membranes, it
is reasonable to speculate as to the possible physiological
significance of dimer formation. Human FXa functions
in vivo either on PS-exposing membranous vesicles derived
from activated platelets (12,14,33,34) or on platelet
membranes having PS exposed on their surfaces (35). The
concentration of human FX in plasma is ~150–200 nM,
and ~100% is activated to FXa in the platelet plug at the siteBiophysical Journal 97(8) 2232–2241
2240 Koklic et al.of injury when platelets are exposed to both collagen and
thrombin (36). The activity of human FXa in solution is
very low (kcat/KM for prothrombin active site formation y
130 M1 s1 at 91 nM FXa), but increases by roughly
500-fold (kcat/KMy 7  104 M1 s1 at 50 mM PS/PC and
5 nM FXa) when bound to PS-containing membranes (6).
Membrane binding produces this rate enhancement by
roughly a 250-fold increase in the rate of the active interme-
diate (meizothrombin) formation and by channeling interme-
diates directly to thrombin without release from the enzyme
(~250-fold) (6). A maximal rate of prothrombin activation
is not obtained until FXa binds to factor Va to form the pro-
thrombinase complex (kcat/KM ~1.2  108 M1 s1 (23)),
roughly another 1800-fold rate enhancement. Recent work
has shown that FXa dimerization and binding to factor Va2
in solution are competitive events (R. Majumder and B. R.
Lentz, unpublished). Thus, it may be that FXa dimerization
and prothrombinase complex formation are competitive
events on a PS-containing membrane, a possibility that we
are currently investigating. The local concentration of
platelet-derived vesicles in the platelet plug is not known,
but it is likely to be high in a mature plug, probably above
the 15–20 mM minimum seen in Fig. 2 B. However, in the
initial wound, before thrombin triggers a burst of platelet
activation, the platelet vesicle concentration could be low.
The concentration of FXa in Fig. 2 B was high (300 nM),
but comparable to the concentration of FX in plasma
(~150–200 nM). Under these conditions, FXa dimerization
on membranes should be possible, depending on the local
free Ca2þ concentration. The free Ca2þ concentration in the
experiments recorded in Fig. 2 B was 4 mM, well above the
free Ca2þ concentration in plasma (~1–1.2 mM). We per-
formed one experiment at 1 mM Ca2þ (inset between
Fig. 2, B and C) and did not observe the anomalous behavior
seen in Fig. 2 B, indicating that FXa did not dimerize under
these conditions. Since FXa dimerization in solution is quite
sensitive to Ca2þ concentration (19,20), dimerization on
a PS-containing membrane is likely to be as well, a possibility
that we are investigating. Depending on the details of the
Ca2þ-dependence of FXa dimerization on membranes, FXa
in the early platelet mass could exist as an inactive dimer,
an active monomer, or in a super-active form complexed
with FVa as platelet activation proceeds. Since Ca2þ concen-
tration in the early wound (platelet plug) drops to ~2/3 that in
plasma (37), the balance between these different forms of FXa
could play an important regulatory role in coagulation. In this
way, PS-containing membranes could turn out to downregu-
late FXa at higher Ca2þ and upregulate it at lower Ca2þ—
a fascinating possibility that demands further investigation.
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